Tesamorelin in the UK: regulatory status

Tesamorelin has no marketing authorisation in the UK. The only regulatory approval for tesamorelin anywhere in the world is the US FDA authorisation for Egrifta, granted in 2010 for HIV-associated lipodystrophy. A European marketing-authorisation application was submitted to the EMA but was withdrawn by the applicant on 21 June 2012 after the agency's Committee for Medicinal Products for Human Use (CHMP) indicated it could not conclude a positive benefit-risk balance^[1]. That withdrawal, which predates Brexit, left tesamorelin without any EU authorisation; the UK has not granted its own since. For UK residents, the regulatory picture flows entirely from that 2012 decision.

This article covers the classification of tesamorelin under UK medicines law, why the CHMP raised objections, what the unlicensed-medicine framework means for supply and access, the import position, WADA prohibition for athletes, and what changed in the past twelve months. It is educational and journalistic. It is not legal or medical advice.

How UK medicines law classifies tesamorelin

The Human Medicines Regulations 2012 define a medicinal product as any substance presented as having properties for treating or preventing disease in humans, or any substance that can be given to humans with a view to restoring, correcting, or modifying physiological functions^[2]. Tesamorelin is a synthetic analogue of growth-hormone-releasing hormone (GHRH) that binds pituitary receptors and stimulates endogenous growth hormone secretion. That pharmacological action is not in dispute. Products sold as 'research-grade tesamorelin' meet the legal definition of a medicinal product when they are offered or used for human purposes, regardless of what the outer label says.

Regulation 46 of those same Regulations prohibits anyone from selling or supplying, or offering to sell or supply, an unauthorised medicinal product^[3]. A product is authorised in the UK when it holds one of four instruments: a UK marketing authorisation, a certificate of registration, a traditional herbal registration, or an Article 126a authorisation. Tesamorelin holds none of these. It is therefore an unauthorised medicinal product under UK law, and selling or supplying it through ordinary commercial channels is not lawful.

The 2012 EMA withdrawal: what the CHMP found

Theratechnologies (the originator, a Canadian company) partnered with Ferrer Internacional for the European marketing-authorisation application. The CHMP began its review and identified a series of concerns across five areas. On 21 June 2012, Ferrer Internacional withdrew the application before the CHMP issued a formal opinion^[1].

The five areas the CHMP flagged were: the fat reduction observed in the trials had not been shown to translate into a clinically meaningful health benefit for patients; the trial participants had larger abdominal fat deposits than European HIV patients typically present with, making the benefit-risk picture uncertain for the European population; elevated insulin-like growth factor 1 (IGF-1) levels in a substantial proportion of treated patients raised a long-term safety concern, including potential cancer risk and complications of diabetic eye disease; no long-term safety data were provided despite the expectation of indefinite treatment; and clinicians would have difficulty distinguishing lipodystrophy-related abdominal fat from ordinary obesity in routine practice^[1].

These are substantive objections, not procedural ones. The applicant withdrew rather than respond to the CHMP's concerns formally. Because the application was withdrawn before a formal opinion was issued, the public record is somewhat thinner than it would be for a formal refusal, but the core position is clear: the CHMP did not consider the benefit-risk balance positive for the European patient population.

No re-application has followed. As of July 2026, the EMA medicine register lists Egrifta under a withdrawn application. Theratechnologies subsequently reformulated the product as Egrifta SV (a more concentrated, smaller-volume preparation) and received FDA approval for it in 2019. The reformulation addresses the injection volume, not the efficacy and safety questions the CHMP raised. The regulatory gap between the US and Europe remains open fourteen years after the 2012 withdrawal.

The only lawful supply route: the specials framework

UK law allows unlicensed medicines to be supplied in one narrow circumstance. Regulation 167 of the Human Medicines Regulations 2012 permits a licensed prescriber to request an unlicensed 'special' product for a specific named patient, provided the product is manufactured or imported against that prescriber's written request^[4]. The prescriber takes clinical responsibility for the decision.

This route requires a licensed UK prescriber on record and, on the supply side, either a Manufacturer's Specials Licence or a Wholesale Dealer's Licence granted by the MHRA, depending on whether the product originates inside or outside the UK. A grey-market vendor shipping vials from the US holds neither.

In practice, most UK prescribers would not request tesamorelin as a special. The approved indication is narrow: HIV-associated lipodystrophy in adults on antiretroviral therapy. A prescriber considering a specials request for that indication would need to document why no authorised alternative covers the patient's needs and be willing to take full GMC liability for an unlicensed prescribing decision where the only pivotal trial evidence comes from a non-European population. For the off-label purposes most commonly discussed online, such as body composition or anti-ageing, no clinical evidence base exists that could justify a specials request under any reasonable reading of prescribing standards.

Importing tesamorelin into the UK

Any business importing an unlicensed medicine from outside the UK must notify the MHRA before import and may only proceed if the MHRA does not object^[5]. Importers from non-approved countries require a Manufacturer's Specials Licence; importers from approved countries require a Wholesale Dealer's Licence. A Qualified Person must certify each batch. These requirements apply to businesses, not to individual travellers.

For private individuals, the UK government's guidance allows a traveller to bring up to three months' supply of a medicine they hold a valid prescription for^[6]. Tesamorelin is not licensed anywhere that would generate a UK-recognisable valid prescription for personal import. Customs can treat parcels of tesamorelin arriving by post as unlicensed medicines and seize them. The 'research use only' label that many vendors print on vials does not change the MHRA's analysis: what matters is whether the substance meets the medicines definition, not the packaging claim.

Tesamorelin is not a controlled drug under the Misuse of Drugs Act 1971. It is not scheduled as Class A, B, or C. Personal possession for non-supply purposes is therefore not a Misuse of Drugs Act offence. This is a different legal question from the supply and import restrictions under the Human Medicines Regulations, which operate independently from the drug-scheduling framework. The distinction matters: being seized at customs is a different outcome from arrest, but it still means the product is lost.

WADA and UK anti-doping status for athletes

For athletes, a separate layer applies. The World Anti-Doping Agency (WADA) prohibits tesamorelin under section S2 of its Prohibited List, which covers peptide hormones, growth factors, growth hormone secretagogues, and mimetics. Tesamorelin is a GHRH analogue that acts on pituitary receptors to stimulate growth hormone release, which is the mechanism S2 targets. The S2 section extends beyond named substances to any agent with a similar chemical structure or biological effect, which means the prohibition holds regardless of whether tesamorelin is listed by name in a given year's text^[7]. UK Anti-Doping (UKAD) applies the WADA Prohibited List to athletes in British sport.

The prohibition covers both in-competition and out-of-competition use, so timing does not create a window. A 2021 paper by Memdouh and colleagues in Drug Testing and Analysis developed a validated liquid chromatography-tandem mass spectrometry method for detecting tesamorelin and three other GHRH analogues in urine samples at limits of detection at or below WADA's required performance threshold^[8]. The analytical capability exists. Athletes should not assume that historical gaps in detection represent a continuing low-risk period.

Because tesamorelin is FDA-approved for HIV-associated lipodystrophy, it occupies a different position from most peptides in this class: a Therapeutic Use Exemption (TUE) application is at least arguable for an athlete with a documented HIV-lipodystrophy diagnosis and no suitable permitted alternative. For athletes using tesamorelin for any other purpose, the TUE pathway is effectively closed. Any athlete in the former situation should contact UKAD before use, not after.

What changed in the past twelve months

The regulatory status of tesamorelin in the UK has not changed. No marketing authorisation was submitted or granted. The MHRA issued no tesamorelin-specific safety alert in the period to July 2026^[1]. The 2012 EMA withdrawal continues to define the UK's inherited starting position.

What has shifted is the volume and nature of online discussion. Tesamorelin has moved from a relatively niche HIV-clinic compound to a substance actively discussed in performance and longevity spaces, often presented alongside the US FDA approval as evidence of general safety or legal acceptability. That framing does not hold. The FDA approval is narrow and jurisdiction-specific. It does not confer any legal status in the UK and does not change the MHRA's position.

On the evidence side, a 2026 meta-analysis by Badran and colleagues, published in Obesity Research and Clinical Practice, confirmed the HIV-lipodystrophy trial outcomes: reductions in visceral adipose tissue, modest lean-mass gain, hepatic fat reduction, with no significant change in blood glucose across pooled data. That is a consolidation of the existing approved indication, not an expansion. There is no new published evidence that would form the basis for a UK marketing-authorisation application in a different indication.

Where this leaves UK residents

For someone with a clinical situation involving HIV-associated lipodystrophy, the path to any access in the UK runs through a prescribing physician willing to initiate a specials request through the MHRA framework. That is a medical route requiring clinical justification, not a consumer pathway. An infectious disease specialist or endocrinologist with HIV medicine experience is the right starting point.

For the much larger group of people asking about tesamorelin for body composition, anti-ageing, or performance purposes: there is no lawful access route in the UK for those uses. The specials framework is indication-specific. Off-label use as a concept starts from an authorised product; tesamorelin has no authorised product here. Online ordering through grey-market vendors involves importing an unauthorised medicinal product without the required licences, and parcels can be seized at the border.

For the cross-country picture, see the tesamorelin peptide page and the UK regulation hub. For the anti-doping picture in more detail, see the tesamorelin WADA status article.

Medical disclaimer: This article is for educational and journalistic purposes only and does not constitute medical advice. Tesamorelin is an unauthorised medicine in the UK. Always consult a qualified healthcare professional before using any peptide product. PeptideMethods.com does not sell, distribute, or facilitate the sale of any peptide product.

Regulatory disclaimer: This page reflects our understanding of UK regulatory status as of 2026-07-27. Regulations change. Verify current status with the MHRA or a qualified UK lawyer before making any decision.